Loading...
XSHE
003017
Market cap278mUSD
Jul 09, Last price  
22.49CNY
1D
3.07%
1Q
-28.03%
IPO
-50.78%
Name

Zhejiang Dayang Biotech Group Co Ltd

Chart & Performance

D1W1MN
XSHE:003017 chart
P/E
18.92
P/S
1.81
EPS
1.19
Div Yield, %
2.67%
Shrs. gr., 5y
-0.41%
Rev. gr., 5y
5.95%
Revenues
1.05b
+14.89%
499,724,931458,565,579448,098,833441,234,459441,234,459554,719,477584,159,118584,159,118621,750,702678,335,139783,209,2771,058,104,9441,058,104,943919,451,375909,955,7171,045,439,587
Net income
100m
+56.64%
26,321,79928,071,64623,666,15528,815,47128,815,47350,256,35970,796,60270,796,60679,497,18891,606,03070,009,32580,726,94880,726,95150,006,70863,746,33899,854,406
CFO
160m
+141.87%
91,644,61957,730,23157,730,23148,950,95948,950,95984,631,60048,638,31538,774,402113,092,957112,488,116091,886,561182,422,54366,193,958160,105,909
Dividend
Oct 24, 20250.3 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang Dayang Biology Technology Co.,Ltd. is a diversified enterprise specializing in the research, development, manufacturing, and global distribution of biological products, agricultural chemicals, and a broad spectrum of chemical compounds. Its extensive product portfolio includes a range of fundamental inorganic chemicals such as potassium carbonate (available in both general and food additive grades) and potassium bicarbonate (also offered as a food additive). They also supply ammonium chloride, catering to both agricultural and industrial needs. Beyond these, the company produces more specialized chemical derivatives, including 2-chloro-6-fluorobenzaldehyde, 2-chloro-6-fluorobenzyl chloride, and various anisole-based products. Furthermore, Zhejiang Dayang is a supplier of veterinary active pharmaceutical ingredients (APIs), exemplified by amprolium HCL, and manufactures veterinary drug premixes, such as enramycin premixes. Established in 1976, the company maintains its headquarters in Jiande, China.
IPO date
Oct 26, 2020
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122021‑122020‑122019‑122019‑002018‑122017‑122017‑002016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT